135049-87-5Relevant academic research and scientific papers
Azetidine derivatives, their preparation and medicaments containing them
-
, (2008/06/13)
The invention concerns compounds of formula (1) wherein: R represents a chain (A) or (B); R1 is methyl or ethyl; R2 is either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R3 and R4, identical or different, are either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R′ represents a hydrogen atom or a —CO—alk radical, their optical isomers, their salts, their preparation and medicines containing them.
Azetidine derivatives, their preparation and pharmaceutical compositions containing them
-
, (2008/06/13)
Compounds of formula: in which R represents a CR1R2, C═C(R5)SO2R6 or C═C(R7)SO2alk radical, their preparation and the pharmaceutical compositions containing them.
DIARYL ETHER HETROCYCLES
-
, (2008/06/13)
The invention concerns a diaryl ether heterocycle of the formula I, or a pharmaceutically-acceptable salt thereof, wherein Ar1 is optionally substituted phenyl or naphthyl; X1 is oxy, thio, sulphinyl or sulphonyl; Ar2 is optionally substituted phenylene, or a 6-membered heterocyclene moiety containing up to three nitrogen atoms; Rl is (l-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(l-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and R2 and R3 together form a group of the formula ?A2?X2?A3? wherein each of A2 and A3 is (l-4C) alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino. The invention also concerns processes for the manufacture of a diaryl ether heterocycle of the formula I, or a pharmaceutically-acceptable salt thereof, and pharmaceutical compositions containing said heterocycle. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.
Diaryl ether heterocycles
-
, (2008/06/13)
The invention concerns a diaryl ether heterocycle of the formula I, or a pharmaceutically-acceptable salt thereof, wherein Ar1 is optionally substituted phenyl or naphthyl;, X1 is oxy, thio, sulphinyl or sulphonyl;, Ar2 is optionally substituted phenylene, or a 6-membered heterocyclene moiety containing up to three nitrogen atoms;, R1 is (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and, R2 and R3 together form a group of the formula -A2-X2-A3- wherein each of A2 and A3 is (1-4C)alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino. The invention also concerns processes for the manufacture of a diaryl ether heterocycle of the formula I, or a pharmaceutically-acceptable salt thereof, and pharmaceutical compositions containing said heterocycle. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.
